Concentration-dependent activity of hydromethylthionine on cognitive decline and brain atrophy in mild to moderate Alzheimer’s disease

Manuscript Number: 

19-0772R1

Author(s): 
Thomas C. Baddeley, Peter Bentham, Luc Bracoud, Harish Ganesan, Serge Gauthier, Jeffrey Hammel, Charles R. Harrington, Jianping Jia, Karin A. Kook, Alison Murray, Gernot Riedel, Christopher M. Rubino, Björn O. Schelter, Helen Shiells, Roger T. Staff, John M.D. Storey, Vesna Vuksanovic, Claude M. Wischik

Disclosures

Thomas C. Baddeley

  • Equity:
    A small number of shares awarded to me during the inception of TauRx in 2002.
    Sponsors:
    Salary
    Patents/Royalties
    I am co-author on several TauRx patents

Peter Bentham

  • Sponsors:
    Employed as Clinical Advisor regarding clinical trial design and conduct.

Luc Bracoud

  • Nothing to Disclose

Harish Ganesan

  • Nothing to Disclose

Serge Gauthier

  • Consulting Fees:
    Boehringer-Ingelheim; TauRx: scientific advisory board member
    Lecture Fees:
    Schwabe: lecture tour
    Grants
    • Agency: 
      CIHR
      Dates: 
      2014-2020
    • Agency: 
      Weston Brain Institute
      Dates: 
      2017-2020

Jeffrey Hammel

  • Nothing to Disclose

Charles R. Harrington

  • Equity:
    I am Chief Scientific Officer in TauRx Therapeutics Ltd and own equity in the company.
    Sponsors:
    I am Chief Scientific Officer in TauRx Therapeutics Ltd and in receipt of payment from the company.
    Patents/Royalties
    I am a named inventor on several patents related to treatment of Alzheimer's disease including the use of LMTM. These patents are currently owned by WisTa Laboratories Ltd., an affiliate of TauRx Therapeutics Ltd.
    Grants
    • Agency: 
      TauRx Therapeutics Ltd
      Dates: 
      2002-2019

Jianping Jia

  • Nothing to Disclose

Karin A. Kook

  • Consulting Fees:
    I am a paid consultant to TauRx (and numerous other companies) and serve on a Scientific Advisory Board for another pharmaceutical company

Alison Murray

  • Patents/Royalties
    Wischik, C. M., Harbaran, D. V., Riedel, G., Deiana, S., Goatman, E. A., Wischik, D. J., Murray, A. D. & Staff, R. T. Phenothiazine compounds for treating mild cognitive impairment 15 Dec 2015 17 Jun 2008 19 Jun 200760/945006. Patent
    Grants
    • Agency: 
      Canon Medical Research Europe
      Dates: 
      01 FEB 2019 - 31 JAN 2022
    • Agency: 
      IXICO
      Dates: 
      Sept 2016-Aug 2019 Co-funded PhD studentship

Gernot Riedel

  • Nothing to Disclose

Christopher M. Rubino

  • Consulting Fees:
    Although I do not personally receive payment directly from TauRx, my firm (ICPD) receives consulting fees from TauRx to conduct PK and PK-PD analyses in support of the development of LMTM. In addition, the work described in this publication was conducted as part of contracted services that ICPD provides to TauRx.
    Grants
    • Agency: 
      TauRx

Björn O. Schelter

  • Sponsors:
    I am paid consultant and subject matter expert for TauRx, the sponsor of the study, as well as GentingTauRxDiagnostics. I consult in various aspects of data analytics and biostatistics.
    Patents/Royalties
    I am co-inventor on various patents related to my TauRx/GentingTauRxDiagnostics role.
    Grants
    • Agency: 
      WistaLab
      Dates: 
      01 Jan 2019 - 31 Dec 2021

Helen Shiells

  • Sponsors:
    Full-time, permanent employee of TauRx Therapeutics Ltd.

Roger T. Staff

  • Consulting Fees:
    I receive consulting fees form TauRx Pharmaceuticals Ltd.
    Sponsors:
    I receive consulting fees form TauRx Pharmaceuticals Ltd.

John M.D. Storey

  • Sponsors:
    employed as Head of technical by TauRx
    Patents/Royalties
    I am a named inventor on a number of patents

Vesna Vuksanovic

  • Nothing to Disclose

Claude M. Wischik

  • Equity:
    I own equity in TauRx Therapeutics Ltd.
    Sponsors:
    I am Chief Executive Officer of TauRx Therapeutics Ltd, the sponsor.
    Patents/Royalties
    Yes. I am a named inventor on several patents related to tau aggregation inhibition and synthesis and use of the active drug in this study. The patents are owned by WisTa Laboratories Ltd., a sister company of TauRx Therapeutics Ltd, and my rights in these patents have been assigned to WisTa.
    Grants
    • Agency: 
      TauRx Therapeutics Ltd
      Dates: 
      Since 2002